Bioequivalence Studies

If two medicines are bioequivalent there is no clinically significant difference in their bioavailability. Although bioequivalence is most commonly discussed in relation to generic medicines, it is important to note that bioequivalence studies are also performed for innovator medicines in some situations such as: between early and late clinical trial formulations or between the formulations used in clinical trials and the product to be marketed for new medicines when changes in formulation have occurred after an innovator product has been approved, for example a change in one or more excipients (inactive ingredients)

  • Pharmacokinetic Studies
  • Pharmacodynamic Studies
  • Clinical Studies
  • IVIVC
  • Earlier exposure on BE

Related Conference of Bioequivalence Studies

August 20-21, 2018

12th Asian Biologics and Biosimilars Congress

Tokyo, Japan
August 29-30, 2018 |

International Conference and Exhibition on Drug Safety & Pharmacovigilance

Park Inn By Radisson Toronto Airport West, 175 Derry Road East, Mississauga, ON, L5T 2Z7, Canada
September 18-19, 2018

6 th European Biopharma Congress

Amsterdam, Netherlands
October 18-20, 2018

18th World Pharma Congress

Warsaw, Poland
November 14-15 | 2018

13th International Conference on Biosimilars and Biologics

Lisbon | Portugal

Bioequivalence Studies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in